The Changing HCV Landscape: Pangenotypic Regimens

The Changing HCV Landscape: Pangenotypic Regimens - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title The Changing HCV Landscape: Pangenotypic Regimens, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : The Changing HCV Landscape: Pangenotypic Regimens
link : The Changing HCV Landscape: Pangenotypic Regimens

Read also


The Changing HCV Landscape: Pangenotypic Regimens

Review Articles
MAY 18, 2017

The Changing HCV Landscape: Update on Treatment

Toward the Future: Pangenotypic Regimens

A novel once-daily RBV-free doublet regimen of ABT-493 (a protease inhibitor) and ABT-530 (an NS5A inhibitor) was studied in an intent-to-treat population of treatment-naive and treatment-experienced patients for 8 to 12 weeks (phase 2 SURVEYOR-1 and SURVEYOR-2). Both drugs are second-generation members of their respective classes, with pangenotypic coverage and coverage of most or all known RAVs relevant to their classes. The results are summarized as follows: SVR12 by 97% to 98% with 8 weeks of treatment in GT1 and GT2 noncirrhotic patients by intention-to-treat analysis,64 96% SVR12 in GT1 patients with cirrhosis treated for 12 weeks,65 and 100% SVR4 for patients with GT4-6 without cirrhosis treated for 12 weeks.66 Additional studies in GT3 patients yielded SVR12 in 97% of noncirrhotics treated for 8 weeks,67 and 100% in cirrhotics treated for 12 weeks.68 These data from phase 2 trials reflect the potential for this regimen to be available in the future as a truly pangenotypic regimen without RBV if phase 3 trials recapitulate these results. A fixed-dose coformulated regimen consisting of SOF-VEL and GS-9857 (a second-generation NS5A inhibitor) received breakthrough therapy designation by the FDA for the treatment of chronic GT1 patients who have previously failed an NS5A-containing regimen. Lawitz et al treated 128 GT1-6 patients, mostly with GT1-3, including 48% with cirrhosis for 12 weeks with the triplet regimen.69 Nearly 80% of patients had prior DAA exposure, including 63 of 63 GT1 patients (100%), and 60% had baseline RAVs. Overall, 127 of 128 (99%) attained SVR12, with the only virologic failure in a GT3 patient. Of 35 patients with prior NS5A exposure, all had SVR12.


Thus articles The Changing HCV Landscape: Pangenotypic Regimens

that is all articles The Changing HCV Landscape: Pangenotypic Regimens This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article The Changing HCV Landscape: Pangenotypic Regimens the link address https://newsaninpiration.blogspot.com/2017/05/the-changing-hcv-landscape-pangenotypic.html

Subscribe to receive free email updates:

Related Posts :

0 Response to "The Changing HCV Landscape: Pangenotypic Regimens"

Post a Comment